ArticleInflammopharmacology2026
Dexamethasone modulates cytokine and chemokine secretion by CD4 + T cells from SSc patients and exerts antifibrotic effects in HOCl-induced SSc mice.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of glucocorticoids in systemic sclerosis (SSc) is restricted due to adverse effects. Despite this, a large proportion of patients still use these medications. Their pharmacological effects on the disease are not completely known; few studies have explored them, and the results are controversial. Thus, the present study aimed to investigate the immunomodulatory and antifibrotic activity of Dexamethasone (Dex) in SSc. The effects were evaluated in CD4 + T lymphocytes and macrophages from 20 SSc patients and 10 healthy volunteers and in a murine model of SSc. Cytokines (IL-4, IL-6, IL-13, IL-17A, and TNF) and chemokines (RANTES, IL-8, MIG, and IP-10) were quantified by sandwich enzyme-linked immunosorbent assay (ELISA) or cytometric bead array (CBA) in cell culture supernatant. Balb/c mice received intradermal injections of hypochlorous acid (HOCl) and treatment with Dex (1 mg/kg) by intraperitoneal injections for 6 weeks. RT-qPCR and histological analysis assessed dermal and pulmonary fibrosis. In the supernatant of CD4 + T lymphocytes, Dex reduced the secretion of IL-4 and IL-13 (p < 0.0001 for both), IL-6 (p = 0.0023) and TNF (p = 0.0005), in addition to the chemokines IP-10, MIG, RANTES, IL-8 (p < 0.0001 for all). Furthermore, Dex treatment SSc mice significantly reduced dermal thickening (p < 0.0001), mRNA expression of Col1a1 (p = 0.002), Tgfβ1 (p < 0.0001) and Acta2 (p < 0.0001) in the skin, and Tgfβ1 (p = 0.005) in the lungs. Furthermore, it reduced IL-4 secretion (p = 0.02) in the splenocyte culture supernatant. In summary, Dex showed immunomodulatory and antifibrotic effects in SSc, evidencing its actions in treating the disease.
Indexed as
Identifiers
41258950What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.